Egalet Corporation has announced that Ascend Therapeutics will begin co-promoting Egalet’s Sprix ketorolac tromethamine nasal spray to women’s healthcare practitioners in the US in the third quarter of 2017 and will continue for at least two years. Financial terms of the deal were not disclosed.
Sprix nasal spray was approved for the short term management of moderate to severe pain in 2010. Egalet acquired Sprix from Luitpold Pharmaceuticals in 2015.
Egalet Executive VP and Chief Operating Officer Mark Strobeck said, “This partnership allows us to augment our commercial effort and bring Sprix nasal spray to patients in a therapeutic area where there is real need. Given the need for effective acute pain treatment options in women’s health, the Ascend team will be able to educate their 9,000 target healthcare providers about the risks and benefits of Sprix nasal spray.”
Ascend President and CEO Jay Bua commented, “The healthcare providers that we are calling on in women’s health are always looking for products that provide relief for short-term, moderate to severe pain that are not narcotics. With Sprix nasal spray, we can offer our target providers an attractive product profile which may benefit many of their patients.”
Read the Egalet press release.
